These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8429349)

  • 41. FDG PET/CT and Bone Scintigraphy in Desmoplastic Fibroma of the Bone.
    Zhang J; Nian S; Bai Y; Dong A
    Clin Nucl Med; 2022 Oct; 47(10):878-881. PubMed ID: 35426851
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Positive [11C]choline and negative [18F]FDG with positron emission tomography in recurrence of prostate cancer.
    Picchio M; Landoni C; Messa C; Gianolli L; Matarrese M; De Cobelli F; Maschio AD; Fazio F
    AJR Am J Roentgenol; 2002 Aug; 179(2):482-4. PubMed ID: 12130458
    [No Abstract]   [Full Text] [Related]  

  • 43. Relative roles of bone scintigraphy and positron emission tomography in assessing the treatment response of bone metastases.
    García JR; Simó M; Soler M; Pérez G; López S; Lomeña F
    Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1243-4. PubMed ID: 16133396
    [No Abstract]   [Full Text] [Related]  

  • 44. Bone scanning in clinical oncology: does it have a future?
    Jacobson AF; Fogelman I
    Eur J Nucl Med; 1998 Sep; 25(9):1219-23. PubMed ID: 9724368
    [No Abstract]   [Full Text] [Related]  

  • 45. [The occasional diagnosis of Plummer's disease during bone scintigraphy with 99mTc-HMDP].
    Saletnich I; Salvatori M; Summaria V; Giordano A
    Radiol Med; 1995 Apr; 89(4):551-4. PubMed ID: 7597246
    [No Abstract]   [Full Text] [Related]  

  • 46. Noninvasive grading of musculoskeletal tumors using PET.
    Adler LP; Blair HF; Makley JT; Williams RP; Joyce MJ; Leisure G; al-Kaisi N; Miraldi F
    J Nucl Med; 1991 Aug; 32(8):1508-12. PubMed ID: 1869970
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incrustation and uptake of skeletal imaging agent in transitional cell carcinoma.
    Taniguchi M; Tatsuta N; Yokota H; Ouguchi M; Higashi K; Okimura T; Yamamoto I
    J Nucl Med; 1997 Aug; 38(8):1206-7. PubMed ID: 9255150
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intraosseous Hibernoma: Five Cases and a Review of the Literature.
    Myslicki FA; Rosenberg AE; Chaitowitz I; Subhawong TK
    J Comput Assist Tomogr; 2019; 43(5):793-798. PubMed ID: 31453977
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of the sensitivity of 99mTc-methyl diphosphonate bone scan with the skeletal X-ray survey in multiple myeloma.
    Tamir R; Glanz I; Lubin E; Vana D; Pick AI
    Acta Haematol; 1983; 69(4):236-42. PubMed ID: 6219530
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The value of bone imaging in multiple myeloma.
    Frank JW; LeBesque S; Buchanan RB
    Eur J Nucl Med; 1982; 7(11):502-5. PubMed ID: 6217073
    [No Abstract]   [Full Text] [Related]  

  • 51. [Positron-emission tomography of the skeletal system using 18FNa: the incidence, pattern of the findings and distribution of benign changes].
    Schirrmeister H; Kotzerke J; Rentschler M; Träger H; Fenchel S; Nüssle K; Diederichs CG; Reske SN
    Rofo; 1998 Sep; 169(3):310-4. PubMed ID: 9779073
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Skeletal Scintigraphy in Radiation-Induced Fibrosis With Lymphedema.
    Wang J; Iranmanesh AM; Oates ME
    Clin Nucl Med; 2017 Mar; 42(3):231-234. PubMed ID: 28033224
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Effectiveness of conventional diagnostic radiology and nuclear medicine in the treatment of pain from bone metastases].
    Genovese EA; Mallardo V; Vaccaro A; Santagata M; Raucci A; D'Agosto G; Fontanarosa A; Schillirò F
    Recenti Prog Med; 2013; 104(7-8):350-5. PubMed ID: 24042406
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The status of nuclear medicine techniques in the diagnosis of bone metastases in breast cancer.
    Makaiová I; Kausitz J; Hupka S; Michaliková B; Vivodová M; Bohunický L
    Czech Med; 1989; 12(1):34-9. PubMed ID: 2498049
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity.
    Okada J; Yoshikawa K; Itami M; Imaseki K; Uno K; Itami J; Kuyama J; Mikata A; Arimizu N
    J Nucl Med; 1992 Mar; 33(3):325-9. PubMed ID: 1740697
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of bevacizumab for bone scintigraphy imaging: A case report.
    Asano T; Takakuwa O; Maeno K; Oguri T; Niimi A
    J Cancer Res Ther; 2015; 11(3):652. PubMed ID: 26458633
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A case of duodenal involvement of multiple myeloma imaged by positron emission tomography with 18F-fluorodeoxyglucose.
    Yasuda S; Hoshikawa T; Yazawa N; Fukumitsu H; Ishikawa K; Suzuki T; Sadahiro S; Shimakura Y; Shibuya M; Nasu S; Tajima T; Makuuchi H
    Tokai J Exp Clin Med; 2001 Dec; 26(4-6):147-51. PubMed ID: 12030445
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Metabolic imaging of a malignant myxofibrosarcoma with F-18-FDG and C-11-methionine positron emission tomography].
    Weckesser E; Redeker J; Kühnel G; Börner AR; Flügel M; Knapp WH
    Nuklearmedizin; 2000; 39(3):N38-9. PubMed ID: 10834199
    [No Abstract]   [Full Text] [Related]  

  • 59. [Comparative study of radiology and bone scintigraphy in multiple myeloma].
    González P; Conte G; Fardella P; Larraín C; Olea E; Garcés N
    Rev Med Chil; 1988 Feb; 116(2):148-52. PubMed ID: 3231929
    [No Abstract]   [Full Text] [Related]  

  • 60. Relevance of the POS-1 orthotopic model as an "imaging model" for in vivo and simultaneous monitoring of tumor proliferation and bone remodeling in osteosarcoma.
    Miot-Noirault E; Gouin F; Dauplat MM; Heymann D; Chezal JM; Redini F
    Cancer Biother Radiopharm; 2012 Feb; 27(1):96-103. PubMed ID: 22217151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.